spacer
home > pmps > winter 2018 > customer centric
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Customer Centric

Major changes in the pharmaceutical and healthcare environments over the past 10 years have driven an urgent need to rethink how medicines are delivered to patients. The heyday of the pharma industry was in the 1980s and 1990s, when a range of blockbuster drugs secured continuous revenues and rapid growth for the major researchled drug makers. Pharma was then a blunt instrument aimed at treating a broad range of conditions, with often as little as a 20% success rate and trialand- error approach. If the first drug did not work, try another until some progress was seen in the patient.

This approach is no longer possible, nor is it acceptable to the healthcare industry or the patients. The information age and growing access to modern medicines around the world have increased expectations. Additionally, due to the complexity of an ageing population, drug patent expiries leading to collapsing revenues, and economic pressure from the payers of healthcare, pharma companies are now expected to demonstrate efficacy and costeffectiveness from day one.

The pharma industry has responded: massive restructuring activities have been undertaken to reduce costs, and advanced research in fields such as pharmacogenomics have opened the door to turn this blunt instrument into a precision tool.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Reed is Marketing and Strategy Director at Amcor Flexibles Healthcare Europe, Middle East, and Africa. He has 19 years of experience in healthcare packaging and has held previous leadership positions in operations and marketing, including managing businesses in Asia-Pacific. Colin is a UK national and holds a Bachelor of Engineering degree and an MBA.
spacer
Colin Reed
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical and Regulatory Operational Excellence Forum

1. Innovative technologies are expected to take clinical development, licensing, and other regulatory processes to the next level in the future. What do you see are the biggest challenges facing companies when trying to cope with continued data growth in a fast changing environment? Pharmaceutical companies are heavily regulated and introducing change needs proof of acceptance by the authorities. The chance that authorities do not agree with that change makes the industry risk averse. Changes in a stable GxP environment are almost by default seen as a risk, however, not adapting to new technologies should also be seen as a risk! Therefore, ICH developed the ICH Q8, Q9, Q10, Q11, and Q12 guidelines, to anticipate change and implement changes much faster, with less of a regulatory burden. Nevertheless, industry is not picking up with the desired pace. Why not?
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 
Industry Events

Pharma Packaging and Labelling East Coast 2019

20-21 February 2019, Phildaelphia, USA

Now in its 11th year, Pharma Packaging and Labeling is back to deliver key, actionable insights into very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labeling chain with both maximum efficiency and minimal cost.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement